FDA Generic Biologic Decision Could Be Prompted With Petition – Barr

Generic drug manufacturers may need to push FDA to make a decision on a pathway for approving generic biologic products by submitting citizen petitions, Barr Research VP-New Drug Development Robert Bill, PhD, told a Center for Business Intelligence conference Nov. 29 in Washington, D.C